Drugs and vascular dementia

Area of Science:

• Neurology
• Geriatrics
• Vascular Medicine

Background:

• Vascular dementia accounts for 20-35% of all dementia cases.
• Etiology is linked to cerebrovascular disease with known risk factors like hypertension, diabetes, smoking, and hyperlipidemia.
• Primary and secondary prevention strategies form the cornerstone of therapeutic approaches.

Purpose of the Study:

• To review the therapeutic landscape for vascular dementia.
• To highlight emerging symptomatic treatments for cognitive disorders associated with vascular dementia.

Main Methods:

• Literature review of cerebrovascular disease and dementia treatments.
• Analysis of current therapeutic guidelines and emerging pharmacological options.

Main Results:

• Established risk factors for vascular dementia include hypertension, diabetes, smoking, and hyperlipidemia.
• Monoamine oxidase inhibitors and acetylcholinesterase inhibitors are recognized for symptomatic treatment.
• Acetylcholinesterase inhibitors are increasingly considered first-line therapy for cognitive deficits in vascular dementia.

Conclusions:

• Effective management of vascular dementia relies on primary and secondary prevention of cerebrovascular disease.
• Pharmacological interventions targeting cognitive symptoms are advancing, with acetylcholinesterase inhibitors showing promise.
• Further research into novel therapeutic targets for vascular dementia is warranted.